Health Care
The dispersion inside one sector. Sector momentum picks where; this is which — and the spread within a sector is wider than the spread between them.
Rank by
Within one sector these rank identically — relative strength is the raw return minus a constant (the sector median), so it cannot change the order. The toggle leads with the number you chose. To see the two axes diverge, use the whole-market view.
Best by vs sector — 50
Return minus the sector’s own median — the discriminator. Showing names that trade at least $1M/day — the tradeable floor. For the untradeable end of the market, see the red list, where the floor comes off.
| # | Company | Raw 12m | vs sector | Capital | $/day |
|---|---|---|---|---|---|
| 1 | ERASErasca, Inc. - Common Stock | +1126.0% | +1126.1% | Compounding | $6.1M |
| 2 | ANROAlto Neuroscience, Inc. Common Stock | +945.9% | +946.0% | Not computable | $3.4M |
| 3 | RLMDRelmada Therapeutics, Inc. - Common Stock | +927.1% | +927.2% | Harvesting | $2.0M |
| 4 | CLYMClimb Bio, Inc. - Common Stock | +830.3% | +830.4% | Diluting | $1.9M |
| 5 | KODKodiak Sciences Inc - Common Stock | +695.0% | +695.1% | Not computable | $14.5M |
| 6 | STTKShattuck Labs, Inc. - Common Stock | +684.1% | +684.2% | Harvesting | $1.2M |
| 7 | ALMSAlumis Inc. - Common Stock | +680.6% | +680.6% | Not computable | $9.1M |
| 8 | CELCCelcuity Inc. - Common Stock | +654.8% | +654.9% | Not computable | $65.1M |
| 9 | DMRADamora Therapeutics, Inc. - Common Stock | +617.9% | +618.0% | Not computable | $1.3M |
| 10 | SLSSELLAS Life Sciences Group, Inc. - Common Stock | +537.4% | +537.5% | Not computable | $11.7M |
| 11 | OVIDOvid Therapeutics Inc. - Common Stock | +512.1% | +512.2% | Compounding | $2.3M |
| 12 | PRAXPraxis Precision Medicines, Inc. - Common Stock | +486.9% | +486.9% | Diluting | $101.0M |
| 13 | ORKAOruka Therapeutics, Inc. - Common Stock | +475.2% | +475.3% | Not computable | $11.7M |
| 14 | SYRESpyre Therapeutics, Inc. - Common Stock | +471.2% | +471.3% | Diluting | $18.2M |
| 15 | IRWDIronwood Pharmaceuticals, Inc. - Class A Common Stock | +468.9% | +469.0% | Not computable | $5.1M |
| 16 | PVLAPalvella Therapeutics, Inc. - Common Stock | +430.1% | +430.1% | Not computable | $16.7M |
| 17 | RLAYRelay Therapeutics, Inc. - Common Stock | +426.1% | +426.2% | Shrinking | $14.1M |
| 18 | DFTXDefinium Therapeutics, Inc. - Common Shares | +424.0% | +424.1% | Diluting | $20.8M |
| 19 | DNTHDianthus Therapeutics, Inc. - Common Stock | +392.5% | +392.5% | Not computable | $25.3M |
| 20 | LQDALiquidia Corporation - Common Stock | +391.8% | +391.9% | Not computable | $55.0M |
| 21 | RVMDRevolution Medicines, Inc. - Common Stock | +379.4% | +379.5% | Diluting | $150.2M |
| 22 | BIOABioAge Labs, Inc. - Common Stock | +370.5% | +370.6% | Not computable | $3.5M |
| 23 | TNGXTango Therapeutics, Inc. - Common Stock | +365.7% | +365.8% | Diluting | $23.1M |
| 24 | FBRXForte Biosciences, Inc. - Common Stock | +348.6% | +348.7% | Not computable | $2.7M |
| 25 | BFLYButterfly Network, Inc. Class A Common Stock | +345.1% | +345.1% | Harvesting | $13.3M |
| 26 | MBXMBX Biosciences, Inc. - Common Stock | +332.9% | +333.0% | Not computable | $13.9M |
| 27 | GLUEMonte Rosa Therapeutics, Inc. - Common Stock | +317.9% | +318.0% | Harvesting | $11.9M |
| 28 | INBXInhibrx Biosciences, Inc. - Common Stock | +301.4% | +301.5% | Not computable | $11.6M |
| 29 | ARWRArrowhead Pharmaceuticals, Inc. - Common Stock | +298.2% | +298.3% | Harvesting | $89.7M |
| 30 | ZURAZura Bio Limited - Class A Ordinary shares | +296.2% | +296.2% | Not computable | $1.9M |
| 31 | CTNMContineum Therapeutics, Inc. - Common stock | +292.0% | +292.0% | Not computable | $1.7M |
| 32 | ANABAnaptysBio, Inc. - Common Stock | +288.6% | +288.6% | Not computable | $18.8M |
| 33 | AVTXAvalo Therapeutics, Inc. - Common Stock | +285.9% | +286.0% | Not computable | $5.4M |
| 34 | IPSCCentury Therapeutics, Inc. - Common Stock | +266.7% | +266.8% | Harvesting | $1.0M |
| 35 | STROSutro Biopharma, Inc. - Common Stock | +266.3% | +266.4% | Not computable | $1.2M |
| 36 | IMMXImmix Biopharma, Inc. - Common Stock | +264.0% | +264.1% | Not computable | $3.5M |
| 37 | FTREFortrea Holdings Inc. - Common Stock | +256.5% | +256.6% | Shrinking | $14.9M |
| 38 | ACRSAclaris Therapeutics, Inc. - Common Stock | +248.1% | +248.2% | Harvesting | $3.0M |
| 39 | DSGNDesign Therapeutics, Inc. - Common Stock | +246.4% | +246.5% | Shrinking | $1.6M |
| 40 | APGEApogee Therapeutics, Inc. - Common Stock | +244.2% | +244.3% | Not computable | $46.0M |
| 41 | BTSGBrightSpring Health Services, Inc. - Common Stock | +242.9% | +243.0% | Compounding | $80.1M |
| 42 | ZNTLZentalis Pharmaceuticals, Inc. - common stock | +239.7% | +239.8% | Harvesting | $1.3M |
| 43 | CRVSCorvus Pharmaceuticals, Inc. - Common Stock | +238.2% | +238.2% | Diluting | $9.7M |
| 44 | COGTCogent Biosciences, Inc. - Common Stock | +237.8% | +237.9% | Diluting | $50.0M |
| 45 | PACSPACS Group, Inc. Common Stock | +235.4% | +235.5% | Compounding | $21.3M |
| 46 | TXG10x Genomics, Inc. - Common Stock | +235.0% | +235.0% | Harvesting | $42.6M |
| 47 | TVTXTravere Therapeutics, Inc. - Common Stock | +232.9% | +233.0% | Not computable | $48.6M |
| 48 | AXGNAxogen, Inc. - Common Stock | +228.5% | +228.6% | Compounding | $21.6M |
| 49 | GHGuardant Health, Inc. - Common Stock | +218.3% | +218.3% | Not computable | $161.5M |
| 50 | AVRAnteris Technologies Global Corp. - Common Stock | +204.9% | +205.0% | Not computable | $1.1M |
What the badges mean
Capital state — what the company is doing with its money
- Compounding
- Capital base growing AND profit growing — deploying money and earning a return on it. NVDA, COST, KLAC.
- Harvesting
- Capital base shrinking via buybacks or deleveraging while profit GROWS. Healthy — Apple, GE. Blue, never a warning colour, and never on the red list.
- Diluting
- Pouring more capital into falling profit — growing revenue while destroying value. INTC, PFE. Red-list eligible.
- Shrinking
- Capital base AND profit both collapsing — the business is evaporating. Fossil, Lumen. Red-list eligible.
- Not computable
- Computed, and there is genuinely not enough filing history to place it. An absence, not a verdict — and distinct from “not computed”, which means we never ran leg 3 for that row at all.
Share class — the row is one company, which may list several classes
- +1
- This company lists N more common classes than the one shown (GOOG/GOOGL, LEN/LEN.B). The row is company-level; the visible ticker is just the label we sort under. The return is priced off the most LIQUID class, not the alphabetically first — hover to see which.
- basis?
- This multi-class company has no volume data, so we cannot say which class priced its return. We do NOT fall back to the first listing — that fallback is the bug that once made a return a fact about the alphabet. Treat this row’s relative strength as unverified.